DMRA
Damora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.06
+7.36%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +98.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +63.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026